Market Overview

UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition

Related IDIX
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
Merck Aims at Superbugs with $9.5B Cubist Buy (Fox Business)

In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating on Idenix Pharmaceuticals (NASDAQ: IDIX), and raised the price target from $5.00 to $24.50.

In the report, Morgan Stanley noted, “We are increasing our price target to $24.50 in light of Merck's announced bid for Idenix at $24.50/share. We do not expect other bidders for this company or any data to cause the deal to not happen...We are Equal-weight IDIX and have a $24.50 price target, which is driven by Merck's announced acquisition price for Idenix. We do not expect other bidders for Idenix.”

Idenix Pharmaceuticals closed on Monday at $23.80.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (IDIX)

Around the Web, We're Loving...

Get Benzinga's Newsletters